Biological Dynamics

About Biological Dynamics

Biological Dynamics operates in the molecular diagnostics sector, focusing on the development of technology for early disease detection. The company was founded in 2010 by Dr. Raj Krishnan, who translated his Ph.D. research in bioengineering from the University of California, San Diego, into a commercial venture. Krishnan's work involved applying AC electrokinetic fields to isolate nanoparticles directly from biological solutions like blood or plasma, a concept that formed the foundation of the company's technology. The company secured over $75 million in funding through multiple rounds to advance its diagnostic platforms.

The core of Biological Dynamics' offering is the ExoVerita™ platform, a lab-on-a-chip system designed for the isolation of exosomes from various biofluids. This technology utilizes a proprietary, patent-protected method called Alternating Current Electrokinetics (ACE) to capture these tiny vesicles, which carry important biomarkers such as DNA, RNA, and proteins from their cells of origin. The platform is designed to provide high-purity and high-yield exosome samples, automating a process that is traditionally complex and time-consuming with methods like ultracentrifugation. The system consists of the ExoVerita Pro instrument, disposable cartridges, and reagents.

The company's business model involves providing this technology to research partners and developing its own diagnostic tests. Through a Technology Access Program, it collaborates with partners to create new diagnostic solutions. Additionally, Biological Dynamics operates its own CAP-accredited, CLIA-certified clinical laboratory in San Diego, where it develops and offers Laboratory Developed Tests (LDTs). One such test is the ExoVita Pancreas assay, aimed at the early detection of pancreatic cancer. In 2021, the FDA granted Breakthrough Device Designation for its liquid biopsy assay for detecting pancreatic ductal adenocarcinoma. However, as of June 2024, the company has ceased operations.